Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ5 | P48544 | 1/20 | 0.42 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863539 | 1.00 | KCNJ5 (0.42) | KCNJ5KCNJ3MAPK14ABL1PDGFRB | |
| SCHEMBL863538 | 1.00 | KCNJ5 (0.42) | KCNJ5KCNJ3MAPK14ABL1PDGFRB | |
| SCHEMBL863999 | 0.84 | GPR139 (0.38) | GPR139CTSAPIK3CD | |
| SCHEMBL15184769 | 0.84 | KCNJ5 (0.41) | KCNJ5KCNJ3MAPK14ABL1PDGFRB | |
| SCHEMBL15184750 | 0.84 | KCNJ5 (0.41) | KCNJ5KCNJ3MAPK14ABL1PDGFRB | |
| SCHEMBL15184749 | 0.84 | KCNJ5 (0.41) | KCNJ5KCNJ3MAPK14ABL1PDGFRB | |
| SCHEMBL864754 | 0.82 | PIK3CD (0.38) | GPR139CTSAPIK3CD | |
| SCHEMBL864285 | 0.81 | MAT2A (0.39) | GPR139CTSAPIK3CD | |
| SCHEMBL865348 | 0.81 | KDM4E (0.45) | SMN1; SMN2GPR139CTSACYP1A2PIK3CD | |
| SCHEMBL865362 | 0.79 | PIP4K2C (0.42) | LMNACYP1A2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396315-B1 | QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-8513284-B2 | Fused pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | KCNJ5 688/4885KCNJ3 984/4885MAPK14 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.